
Sign up to save your podcasts
Or


The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?
Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.
Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts
Hosted on Acast. See acast.com/privacy for more information.
By The Economist4.7
115115 ratings
The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?
Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.
Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts
Hosted on Acast. See acast.com/privacy for more information.

7,718 Listeners

4,171 Listeners

891 Listeners

921 Listeners

521 Listeners

2,062 Listeners

767 Listeners

942 Listeners

588 Listeners

827 Listeners

364 Listeners

112 Listeners

265 Listeners

107 Listeners

2,552 Listeners

46 Listeners

1,078 Listeners

1,410 Listeners

102 Listeners

37 Listeners

891 Listeners

371 Listeners

498 Listeners

80 Listeners

74 Listeners

100 Listeners

263 Listeners